T-1301, a multi-targeted anti-cancer developmental drug candidate, is licensed from The National Health Research Institutes to Taivex Therapeutics Corp.
Taivex Therapeutics Corp. (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1301 (formerly, DBPR216), a potential anti-cancer developmental drug candidate, effective on April 8. T-1301 is a novel small molecular multi-target tyrosine kinase inhibitor (TKI), which is orally available and exhibited potent inhibitory efficacy against both wild …